AAM and Biosimilars Council Statement on ACA Ruling in California v. Texas

Thursday June 17, 2021

WASHINGTON, DC – (June 17, 2021) AAM and its Biosimilars Council welcome today’s decision by the U.S. Supreme Court in California v. Texas that ensures America’s patients and taxpayers can continue to benefit from biosimilar access and competition in the marketplace that is made possible by the Affordable Care Act’s inclusion of a biosimilar pathway.

MEDIA CONTACT:
Rachel Schwartz
202.249.7147


About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:

GRx+Biosims 2021 Conference

Join us on November 8-10 in Bethesda, MD. GRx+Biosims 2021 is the premier scientific and regulatory event for the U.S. generics and biosimilars industry.

LEARN MORE

Recent Tweets